Skip to main content
. Author manuscript; available in PMC: 2013 Nov 21.
Published in final edited form as: Handb Exp Pharmacol. 2009;(191):10.1007/978-3-540-68964-5_21. doi: 10.1007/978-3-540-68964-5_21

Figure 2.

Figure 2

Effect of BAY 58–2667 administration on (A) mean arterial pressure (MAP), (B) systemic vascular resistance, (C) right atrial pressure (RAP), (D) pulmonary capillary wedge pressure (PCWP), (E) cardiac output (CO), and (F) renal blood flow (RBF). * indicates p<0.05 compared to baseline. Taken from Boerrigter et al. (2007).